|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300078871 |
|
最近更新日期: Date of Last Refreshed on: |
2023-12-20 11:08:31 |
|
注册时间: Date of Registration: |
2023-12-20 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
“脾胃转枢”理论视角下的电针干预肿瘤相关肌少症的效应规律研究 |
|
Public title: |
Study on the effect of electroacupuncture on tumor-related sarcopenia from the perspective of "pivot of the spleen and stomach" theory |
|
注册题目简写: |
电针干预肿瘤相关肌少症 |
|
English Acronym: |
Electroacupuncture intervention of tumor-associated sarcopenia |
|
研究课题的正式科学名称: |
“脾胃转枢”理论视角下的电针干预肿瘤相关肌少症的效应规律研究 |
|
Scientific title: |
Study on the effect of electroacupuncture on tumor-related sarcopenia from the perspective of "pivot of the spleen and stomach" theory |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
程长城 |
研究负责人: |
何玮玮 |
|
Applicant: |
Changcheng Cheng |
Study leader: |
Weiwei He |
|
申请注册联系人电话: Applicant telephone: |
+86 138 1402 5396 |
研究负责人电话:
Study leader's |
+86 138 1400 6619 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
ccnutcm@163.com |
研究负责人电子邮件: Study leader's E-mail: |
heweiwei1983@hotmail.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
南京浦口区中医院 |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
|
|
申请注册联系人通讯地址: |
江苏省南京市浦口区江浦街道公园北路18号 |
研究负责人通讯地址: |
江苏省南京市浦口区江浦街道公园北路18号 |
|
Applicant address: |
No. 18 Park North Road, Jiangpu Street, Pukou District, Nanjing City, Jiangsu Province |
Study leader's address: |
No. 18 Park North Road, Jiangpu Street, Pukou District, Nanjing City, Jiangsu Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
南京市浦口区中医院 |
||
|
Applicant's institution: |
Nanjing Pukou Hospital of TCM |
||
|
研究负责人所在单位: |
南京市浦口区中医院 |
||
|
Affiliation of the Leader: |
Nanjing Pukou Hospital of TCM |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
20230040 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
南京市浦口区中医院伦理委员会办公室 |
||
|
Name of the ethic committee: |
Ethics Committee Office, Nanjing Pukou Hospital of TCM |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-07-07 00:00:00 | ||
|
伦理委员会联系人: |
豆娟莉 |
||
|
Contact Name of the ethic committee: |
Juanli Dou |
||
|
伦理委员会联系地址: |
江苏省南京市浦口区江浦街道公园北路18号 |
||
|
Contact Address of the ethic committee: |
No. 18 Park North Road, Jiangpu Street, Pukou District, Nanjing City, Jiangsu Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 189 1331 0995 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
南京市浦口区中医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Nanjing Pukou Hospital of TCM |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
江苏省南京市浦口区江浦街道公园北路18号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 18 Park North Road, Jiangpu Street, Pukou District, Nanjing City, Jiangsu Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
经费部分来自医院拨款,部分为浦口区科技局支持。 |
||||||||||||||||||||||
|
Source(s) of funding: |
Part of the funding comes from the hospital, and part is supported by Pukou Science and Technology Bureau. |
||||||||||||||||||||||
|
研究疾病: |
肌少症 |
||||||||||||||||||||||
|
Target disease: |
sarcopenia |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
I期临床试验 | ||||||||||||||||||||||
|
Study phase: |
1 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
肿瘤和肌少症均以“脾病而枢机不利”为发病的共同土壤,立足于二者关乎脾胃的共性病机,进一步探讨肿瘤相关性肌少症的中医防治方案。本项目采用单盲、随机、对照的研究方式,以符合肌少症诊断标准的肿瘤患者为研究对象,设立电针联合营养干预组,单纯营养干预组,对比分析两组的肌肉相关指标,评价两组对肿瘤相关性肌少症的有效性和安全性。紧扣“健脾助运”发挥中医“以证统病,异病同治”的特色优势,破解老年人多病管理的临床难题,提高老年患者的生活质量,为肿瘤相关性肌少症这样的慢病管理提供新的临床路径。 |
||||||||||||||||||||||
|
Objectives of Study: |
Based on the common pathogenesis of spleen and stomach, tumor and sarcopenia are both common soil. The prevention and treatment of tumor related sarcopenia is further discussed. In this project, tumor patients meeting the diagnostic criteria for sarcopenia were selected as subjects in a single-blind, randomized and controlled study. A combination of electroacupuncture and nutrition intervention group and a simple nutrition intervention group were set up to compare and analyze the muscle-related indicators of the two groups, and evaluate the effectiveness and safety of the two groups for tumor-related sarcopenia. Closely follow the "invigorating spleen" to give play to the characteristic advantages of traditional Chinese medicine "combining disease with syndrome and treating different diseases together", crack the clinical problems in the management of elderly patients with multiple diseases, improve the quality of life of elderly patients, and provide a new clinical path for the management of chronic diseases such as tumor-related sarcopenia. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1)经过病理学检查确诊的肿瘤患者,预计生存周期三个月以上;(2)患者主动活动能力、平衡和协调功能良好;(3)自愿参加本研究并签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
(1) Patients with tumor diagnosed by pathological examination are expected to survive for more than three months; (2) The patient had good active activity, balance and coordination; (3) Volunteer to participate in the study and sign the informed consent. |
||||||||||||||||||||||
|
排除标准: |
(1)肌少症分层中合并功能障碍的肌少症;(2)因心理因素害怕针刺、无法接受针刺治疗者;(3)易发生各类急性并发症。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) sarcopenia with dysfunction in the sarcopenia stratification; (2) Those who are afraid of acupuncture due to psychological factors and cannot accept acupuncture treatment; (3) Prone to various acute complications. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-09-01 00:00:00至 To 2025-09-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-01-01 00:00:00 至 To 2024-11-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由课题参与人罗铮将全部入选患者按就诊顺序编号,采用SPSS25.0软件设定种子数(seed)进行随机化分配,依次装入不透明信封中,由专人保管。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Luo Zheng, the participant of the study, number all the selected patients according to the order of treatment, use SPSS25.0 software to set the seed number for random allocation, and place them in opaque envelopes successively for special care. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
单盲 由不知分组情况的专员进行疗效评价,其次在资料总结阶段采用盲法统计分析 |
|
Blinding: |
single blind method The efficacy evaluation is conducted by a specialist who is unaware of the grouping situation, followed by blind statistical analysis in the data summary stage. |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
No |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集和管理主要有病例记录表,暂无电子采集和管理系统。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection and management mainly include Case Record Form, and there is no electronic collection and management system. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |